Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

During Radiotherapy for Squamous Cell Head and Neck Cancer, Should Cisplatin Be Given Weekly at Low Dose or Every Three Weeks at High Dose?

During Radiotherapy for Squamous Cell Head and Neck Cancer, Should Cisplatin Be Given Weekly at Low Dose or Every Three Weeks at High Dose?

For inoperable or surgically unsuitable locally advanced squamous cell head and neck cancer patients, chemotherapy concurrently with radiotherapy is standard treatment. In addition, after cancer surgery , positive surgical margins, involvement of multiple lymph nodes and metastatic lymph nodes with breached capsules—patients at high regional recurrence risk—are reasons to use preventive (adjuvant) radiotherapy concurrently with cisplatin chemotherapy to improve regional disease control and reduce recurrence and mortality risks.

Radiotherapy is given concurrently with cisplatin at a dose every three weeks of 100 mg per square meter, calculated by body surface area. Adding chemotherapy aims both to improve radiotherapy efficacy and to eliminate microscopic metastases dispersed through the body during tumor formation, minimizing future recurrence risk.

For years, high-dose cisplatin every three weeks concurrently with radiotherapy has caused tolerance difficulties, prompting physicians to use lower doses weekly. Weekly low-dose cisplatin is preferred particularly in older patients and those with comorbidities because it reduces side effects and facilitates management. While high-dose cisplatin every three weeks has proven efficacy, the benefit of weekly low-dose cisplatin and its equivalence to the three-weekly schedule had not been proven. Noronha and colleagues, in Journal of Clinical Oncology, published a phase III randomized clinical studyanswering this important question.

The study compared cisplatin concurrently with radiotherapy at 30 mg per square meter weekly versus 100 mg every three weeks. Two important questions, one primary, defined its objective. The first and main question was whether weekly low-dose cisplatin provides regional disease control (local control) as effectively as high-dose cisplatin every three weeks. The second was whether survival differs between these treatments.

Between 2013 and 2017, two hundred seventy-nine postoperative patients (% 93) and 21 inoperable patients were enrolled. Over two years of follow-up, regional disease control was % 58 in the weekly low-dose cisplatin group versus % 73 in the high-dose every-three-weeks group. These numerically striking results were also statistically significant. As expected, side effects were greater with high-dose cisplatin every three weeks.

No difference in overall survival was found between the two treatment arms.

In conclusion, for patients in suitable general condition who can receive high-dose treatment every three weeks, cisplatin at 100 mg per square meter should be chosen. Weekly treatment should not be preferred unless necessary. By showing that weekly low-dose cisplatin, sometimes used in routine practice to reduce side effects, is insufficient in head and neck cancer treatment, this study has provided the scientific community with an answer to an important question.

The infographic poster below provides basic information about head and neck cancers

27 july world oral head and neck cancer day cancer symptoms risk factors

Sources

Vanita Noronha.
Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.
Journal of Clinical Oncology, 2017

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

During Radiotherapy for Squamous Cell Head and Neck Cancer, Should Cisplatin Be Given Weekly at Low Dose or Every Three Weeks at High Dose?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy